Towards a Treatment for Leukodystrophy Using Cell-Based Interception and Precision Medicine.

POLR3-related leukodystrophy (POLR3-HLD) SCoPE2-MS cell-based interception and precision medicine induced pluripotent stem cells leukodystrophy proteomics single-cell technologies

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
17 Jul 2024
Historique:
received: 23 05 2024
revised: 12 07 2024
accepted: 14 07 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 27 7 2024
Statut: epublish

Résumé

Cell-based interception and precision medicine is a novel approach aimed at improving healthcare through the early detection and treatment of diseased cells. Here, we describe our recent progress towards developing cell-based interception and precision medicine to detect, understand, and advance the development of novel therapeutic approaches through a single-cell omics and drug screening platform, as part of a multi-laboratory collaborative effort, for a group of neurodegenerative disorders named leukodystrophies. Our strategy aims at the identification of diseased cells as early as possible to intercept progression of the disease prior to severe clinical impairment and irreversible tissue damage.

Identifiants

pubmed: 39062571
pii: biom14070857
doi: 10.3390/biom14070857
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Benoit Coulombe (B)

Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal, Montréal, QC H2W 1R7, Canada.
Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC H3T 1A8, Canada.

Alexandra Chapleau (A)

Department of Neurology and Neurosurgery, Pediatrics and Human Genetics, McGill University, Montréal, QC H9X 3V9, Canada.
Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montréal, QC H4A 3J1, Canada.
The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montréal, QC H9X 3V9, Canada.

Julia Macintosh (J)

Department of Neurology and Neurosurgery, Pediatrics and Human Genetics, McGill University, Montréal, QC H9X 3V9, Canada.
Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montréal, QC H4A 3J1, Canada.

Thomas M Durcan (TM)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montréal, QC H9X 3V9, Canada.

Christian Poitras (C)

Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal, Montréal, QC H2W 1R7, Canada.

Yena A Moursli (YA)

Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal, Montréal, QC H2W 1R7, Canada.

Denis Faubert (D)

Mass Spectrometry and Proteomics Platform, Institut de Recherches Cliniques de Montréal, Montréal, QC H2W 1R7, Canada.

Maxime Pinard (M)

Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal, Montréal, QC H2W 1R7, Canada.

Geneviève Bernard (G)

Department of Neurology and Neurosurgery, Pediatrics and Human Genetics, McGill University, Montréal, QC H9X 3V9, Canada.
Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montréal, QC H4A 3J1, Canada.
Department Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montréal, QC H4A 3J1, Canada.

Classifications MeSH